Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALEVE vs COMBOGESIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
COMBOGESIC (acetaminophen and tramadol) combines a centrally acting analgesic (tramadol) that binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake, with an antipyretic (acetaminophen) that inhibits cyclooxygenase (COX) in the CNS.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain,Fever
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
One tablet (acetaminophen 500 mg / tramadol 37.5 mg) orally every 4 to 6 hours as needed for pain, not to exceed 8 tablets per day.
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Acetaminophen: 2-3 hours; Tramadol: 6.3 hours (slow CYP2D6 metabolizers may exceed 12 hours). Clinically, dosing interval adjusted for renal impairment.
Naproxen is extensively metabolized in the liver primarily via CYP2C9 to 6-O-desmethyl naproxen, and less than 5% is excreted unchanged in urine.
Tramadol: primarily metabolized by CYP2D6 and CYP3A4; O-desmethyltramadol (active metabolite) via CYP2D6. Acetaminophen: primarily metabolized by glucuronidation and sulfation in the liver.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Renal excretion of acetaminophen metabolites (glucuronide, sulfate, cysteine, and mercapturate conjugates); 85% total. Tramadol and metabolites: 90% renal, 10% fecal.
>99% bound to albumin; saturable at high concentrations.
Acetaminophen 10-25%; Tramadol 20% bound to albumin.
0.16 L/kg; indicates distribution primarily in extracellular fluid.
Acetaminophen 0.9 L/kg; Tramadol 2.6 L/kg. Reflects extensive tissue distribution.
Oral: ~95%; immediate-release formulation.
Acetaminophen oral ~88%; Tramadol oral ~75% (due to first-pass metabolism).
GFR 30-59 m L/min: reduce dose and avoid long-term use; GFR <30 m L/min: contraindicated.
For Cr Cl 30-59 m L/min: increase dosing interval to every 12 hours, maximum 4 tablets per day. For Cr Cl <30 m L/min: not recommended. Hemodialysis: administer dose after dialysis session, use with caution.
Child-Pugh class A: no adjustment; Child-Pugh class B or C: avoid use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% or extend interval; maximum 4 tablets per day. Child-Pugh Class C: contraindicated.
2-12 years: 2.5-5 mg/kg/dose orally every 8-12 hours; maximum 10 mg/kg/day. 12 years and older: same as adult.
Not recommended for pediatric use. Safety and efficacy not established in children.
Initiate at lowest effective dose (220 mg every 12 hours); maximum 440 mg per day; monitor renal function and GI bleeding risk.
Initiate at lowest effective dose; consider extended dosing interval (every 8-12 hours) and monitor for adverse effects, particularly CNS and respiratory depression.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Naproxen is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risk of medication errors (combining different forms of acetaminophen leading to hepatotoxicity); serious, life-threatening, or fatal respiratory depression may occur when used with benzodiazepines or other CNS depressants.
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure and edema,Renal toxicity,Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic toxicity (inhibition of platelet aggregation),Exacerbation of asthma,Hepatic effects,Pregnancy: avoid during third trimester
Addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity (associated with acetaminophen); seizures; serotonin syndrome; risk of overdose; interactions with MAOIs; CYP2D6 poor metabolizers may have reduced efficacy; risk of anaphylaxis and hypersensitivity.
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in the setting of CABG surgery,Advanced renal disease,History of gastrointestinal bleeding or perforation related to previous NSAID therapy,Active gastrointestinal bleed
Hypersensitivity to tramadol, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; concomitant use of MAOIs or within 14 days of such therapy.
Avoid concurrent use of alcohol as it increases GI bleeding risk. No specific food restrictions; taking with food or milk may reduce dyspepsia. High potassium foods (e.g., bananas, spinach) may increase hyperkalemia risk in patients with renal impairment.
Avoid alcohol while taking Combogesic, as it increases the risk of liver damage with acetaminophen and gastrointestinal bleeding with ibuprofen. Taking with food may reduce gastric irritation. No specific food restrictions.
First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arteriosus premature closure risk begins. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, necrotizing enterocolitis, intracranial hemorrhage, and renal impairment; avoid after 30 weeks.
Combogesic contains paracetamol (acetaminophen) and tramadol. Paracetamol: No increased risk of major malformations; first trimester use is generally considered low risk. Second and third trimester: No known fetal toxicity at therapeutic doses. Tramadol: First trimester: Limited data, but no major teratogenicity observed in animal studies; human data insufficient to exclude risk. Second and third trimester: Not associated with structural anomalies; chronic use may lead to fetal dependence and neonatal withdrawal syndrome. At term: Risk of neonatal respiratory depression if used near delivery; tramadol may prolong labor and increase risk of postpartum hemorrhage.
Excreted in breast milk in low concentrations (M/P ratio ~0.12); relative infant dose <1% of maternal weight-adjusted dose. Compatible with breastfeeding; monitor infant for potential adverse effects (gastrointestinal upset, rash) at higher doses.
Paracetamol: Excreted into breast milk in small amounts (M/P ratio ~0.23-0.91); considered compatible with breastfeeding. Tramadol: Excreted into breast milk (M/P ratio ~1.5-2.0); relative infant dose ~2.24% of maternal weight-adjusted dose. Monitor infant for sedation and respiratory depression; avoid in women with CYP2D6 ultra-rapid metabolizer status due to increased risk of high morphine levels in breast milk.
No specific pharmacokinetic-based dose adjustments; however, use lowest effective dose for shortest duration, especially after 20 weeks. Avoid use after 30 weeks gestation due to fetal risks. Increased volume of distribution may reduce serum concentrations but no dose adjustment recommended.
Paracetamol: No adjustment required; use lowest effective dose for shortest duration. Tramadol: Pregnancy may alter tramadol pharmacokinetics (increased clearance, decreased Cmax); however, no standard dose adjustment is recommended. Use minimal effective dose; avoid sustained-release formulations. Near term: Consider alternative analgesics to minimize neonatal effects.
ALEVE (naproxen sodium) is a nonsteroidal anti-inflammatory drug (NSAID) with a longer half-life (12-17 hours) allowing twice-daily dosing. It carries a boxed warning for cardiovascular and gastrointestinal risk. Use lowest effective dose for shortest duration. Contraindicated in patients with aspirin allergy, perioperative pain in CABG surgery, and significant renal impairment. Monitor renal function in elderly, volume-depleted patients, and those on ACE inhibitors or diuretics.
Combogesic (paracetamol/acetaminophen + ibuprofen) is a fixed-dose combination used for acute pain. Note that the maximum daily dose of acetaminophen is 4000 mg (or lower in hepatic impairment) and ibuprofen 1200 mg (or lower in renal impairment). Avoid concomitant use of other NSAIDs or acetaminophen-containing products. Use with caution in patients with a history of peptic ulcer or bleeding disorders; ibuprofen may increase bleeding risk.
Take with food or milk to reduce GI upset.,Do not exceed 2 tablets (440 mg) in 24 hours unless directed by a doctor.,Avoid alcohol consumption to lower risk of GI bleeding.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not use with other NSAIDs (e.g., ibuprofen, aspirin) unless prescribed.
Do not exceed the recommended dose as it may cause liver damage or kidney problems.,Avoid taking other products containing acetaminophen or NSAIDs (e.g., ibuprofen, naproxen) while using Combogesic.,Take with food or milk to reduce stomach upset.,Report any signs of stomach bleeding (e.g., black/tarry stools, vomiting blood), rash, or swelling.,Do not use for more than 10 days for pain unless directed by a doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALEVE vs COMBOGESIC, answered by our medical review team.
ALEVE is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.. COMBOGESIC is a Analgesic Combination (Opioid + Non-Opioid) that works by COMBOGESIC (acetaminophen and tramadol) combines a centrally acting analgesic (tramadol) that binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake, with an antipyretic (acetaminophen) that inhibits cyclooxygenase (COX) in the CNS.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALEVE and COMBOGESIC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALEVE is: 220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.. The standard adult dose of COMBOGESIC is: One tablet (acetaminophen 500 mg / tramadol 37.5 mg) orally every 4 to 6 hours as needed for pain, not to exceed 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALEVE and COMBOGESIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALEVE is classified as Category C. First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arter. COMBOGESIC is classified as Category C. Combogesic contains paracetamol (acetaminophen) and tramadol. Paracetamol: No increased risk of major malformations; first trimester use is generally considered low risk. Second an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.